Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press release dated June 27, 2019 that Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company announced that the underwriters of its recently closed underwritten public offering of 7,000,000 ordinary shares have exercised in full their option to purchase an additional 1,050,000 ordinary shares at the public offering price of $5.00 per share. The aggregate gross proceeds to Gamida from the offering, including the shares sold pursuant to the underwriters’ option, before deducting underwriting discounts and commission and estimated offering expenses, were $40.25 million. The Company holds approximately 62% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTCM) (approximately 40% on a fully diluted basis) which, in turn, holds approximately 2.7 million shares in Gamida, representing approximately 8% of Gamida's outstanding share capital (approximately 7% on a fully diluted basis).
Tel Aviv, Israel, June 03, 2019 -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today that Insightec Ltd. ("Insightec") announced today that ...
Tel Aviv, Israel, June 12, 2019 -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) ("Elbit" or the "Company") announced today that the Company and its (Series I) Noteholders approved.
Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, that its Board of Directors approved the filing of a Form 15F with the Securities and Exchange Commission ("SEC") to voluntarily deregister its ordinary shares under Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act"). The Company will file today the Form 15F.
CHICAGO , Nov. 11, 2019 /PRNewswire/ -- Mesirow Financial ("Mesirow" or the "firm") today announced the recent appointments of three executives with proven track records of driving ...
Tel Aviv, Israel, June 27, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press release dated June 25, 2019 that on June 27, 2019, Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35 million, before deducting underwriting discounts and commission and estimated offering expenses. In addition, Gamida has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on June 26, 2019.
Tel Aviv, Israel, July 10, 2019 -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today that Insightec Ltd. ("Insightec") announced today FDA....
Tel Aviv, Israel, July 03, 2019 -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press releases dated December 18, 2017.
TEL AVIV, Israel, July 25, 2019 -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated May 27, 2019,.
Tel Aviv, Israel, June 19, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today that on June 19, 2019, Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company announced that Gamida and Lonza Group Ltd ("Lonza") have entered into a strategic manufacturing agreement for the future commercial production after potential FDA approval of omidubicel (formerly known as NiCord) in patients with hematologic malignancies. In February 2016, Gamida entered into a five-year Manufacturing Services Agreement with Lonza US according to which Lonza US manufactures, packages, ships, and handles quality assurance and control products, based on statements of work, which Gamida submit with respect to each development of a process or product.
Tel Aviv, Israel, June 25, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today that on June 24, 2019, Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company announced the launch of a proposed follow-on public offering of approximately $30.0 million of its ordinary shares (approximately 4.04 million shares). In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to $4.5 million of additional ordinary shares (up to 606,000 shares) at the public offering price, less underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.